ARS Pharmaceuticals (SPRY) Earnings Date, Estimates & Call Transcripts $12.89 +0.53 (+4.29%) Closing price 04:00 PM EasternExtended Trading$12.93 +0.04 (+0.28%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARS Pharmaceuticals Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 8Before Market OpensEstimatedActual EPS (Mar. 20) $0.52 Beat By $0.56 Consensus EPS (Mar. 20) -$0.04 ARS Pharmaceuticals issued Q4 2024 earnings on March 20, 2025, reporting an EPS of $0.52, which topped analysts' consensus estimates of -$0.04 by $0.56. Quarterly revenue was reported to be $86.58 million, above the consensus estimate of $15.46 million. With a trailing EPS of $0.08, ARS Pharmaceuticals' earnings are expected to grow next year, from ($0.55) to ($0.17) per share. Conference CallSPRY Upcoming EarningsARS Pharmaceuticals' next earnings date is estimated for Thursday, May 8, 2025, based off prior year's reporting schedules. Get ARS Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSPRY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SPRY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads ARS Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.35-$0.35-$0.35Q2 20251-$0.32-$0.32-$0.32Q3 20251-$0.36-$0.36-$0.36Q4 20251-$0.36-$0.36-$0.36FY 20254($1.39)($1.39)($1.39) Remove Ads ARS Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)-------3/20/2025Q4 2024-$0.04$0.52+$0.56$0.52$15.46M$86.58M8/6/2024Q2 2024-$0.12-$0.13 -$0.01-$0.13$2.00M$0.50M5/9/2024--$0.11-$0.11--$0.11--3/21/2024Q4 2023-$0.14-$0.07+$0.07-$0.07--11/9/2023Q3 2023-$0.18-$0.16+$0.02-$0.16--8/10/2023Q2 2023-$0.17-$0.18 -$0.01-$0.18-$0.01M5/15/2023Q1 2023-$0.17-$0.16+$0.01-$0.16-$0.02M ARS Pharmaceuticals Earnings - Frequently Asked Questions When is ARS Pharmaceuticals's earnings date? ARS Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on SPRY's earnings history. Did ARS Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, ARS Pharmaceuticals (NASDAQ:SPRY) reported $0.52 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.04) by $0.56. Learn more on analysts' earnings estimate vs. SPRY's actual earnings. How can I listen to ARS Pharmaceuticals's earnings conference call? The conference call for ARS Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How much revenue does ARS Pharmaceuticals generate each year? ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded annual revenue of $89.15 million. How much profit does ARS Pharmaceuticals generate each year? ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded net income of -$54.37 million. SPRY has generated $0.08 earnings per share over the last four quarters. What is ARS Pharmaceuticals's EPS forecast for next year? ARS Pharmaceuticals's earnings are expected to grow from ($0.55) per share to ($0.17) per share in the next year. More Earnings Resources from MarketBeat Related Companies PTC Therapeutics Earnings ADMA Biologics Earnings Zai Lab Earnings Organon & Co. Earnings Avidity Biosciences Earnings Arcellx Earnings SpringWorks Therapeutics Earnings Ultragenyx Pharmaceutical Earnings Akero Therapeutics Earnings Viking Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of Earnings Remove Ads This page (NASDAQ:SPRY) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis could put Trump on new $100 billAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
